Cholangiocarcinoma News

Toxicities Associated with FGFR Inhibitors

Videos — April 2, 2020

Featuring:

Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers
Angela Lamarca, MD, PhD, MSc
Consultant (FEA) in Medical Oncology
HPB-NET–Gastrointestinal Tumors Group, Department of Oncology
Fundación Jiménez Díaz University Hospital
Autonomous University of Madrid
Madrid, Spain
Vaibhav Sahai, MBBS, MS
University of Michigan
Rogel Cancer Center
Ann Arbor, MI

Dr Vaibhav Sahai reviews the toxicities that have been encountered in clinical trials with FGFR inhibitors. He suggests that most of these adverse events are class effects and include hyperphosphatemia (which is relatively easy to manage with dietary restrictions and phosphate-binding agents), nail and hair changes, stomatitis, and retinal epithelial changes. In contrast, Dr Angela Lamarca considers the adverse events associated with chemotherapy, including myelosuppression, nausea, vomiting, diarrhea, and others. Dr Milind Javle suggests that the toxicities encountered with chemotherapy are significantly worse than those with FGFR inhibitors.

Related Items

Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
CCA Summit Live from ESMO GI 2022
By Angela Lamarca, MD, PhD, MSc
Videos
Angela Lamarca, MD, PhD, MSc, Consultant (FEA) in Medical Oncology presents an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2022 annual meeting of the ESMO World Congress on Gastrointestinal Cancer (ESMO GI 2022).
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Videos
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.
Immuno-Oncology in Biliary Tract Cancers
By Vaibhav Sahai, MBBS, MS
Videos
Dr V. Sahai discusses how to move forward with immune-oncology approaches in biliary tract cancers, including key investigations that are needed to improve outcomes with immunotherapy in CCA.
The Future of Chemotherapy in CCA
By Juan W. Valle, MB ChB, MSc, FRCP; Angela Lamarca, MD, PhD, MSc
Videos
Drs Juan Valle and Angela Lamarca discuss clinical studies being conducted to improve the use of chemotherapy in CCA by exploring molecular biomarkers that could help patient selection for optimal response to certain chemotherapy regimens.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: